KALA BIO, Inc. (KALA) Q3 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the COLA Pharmaceuticals conference call to review its third quarter financial results in the acquisition of Combangio. Please note that this live presentation that was designed to accompany this conference call is available on COLA's website, colarx.com, as well as through the webcast player. At this time, all participants are in a listen-only mode. Following management's prepared remarks, a Q&A session will be held. As a reminder, this call is being recorded. I would now like to turn the call over to Jill Steyer, Executive Director, Investor Relations and Corporate Communications for Cala Pharmaceuticals. Please proceed. Jill Steyer Thank you, Operator, and thank you all for participating in today's call. Earlier today, we issued two press releases, one announcing our third quarter financial results and recent business highlights, and the other announcing our acquisition of Cambagio and its lead asset, CNB 012, which we have renamed KPI 012. a novel cell-free secretome therapy currently in clinical development for persistent cornelial epithelial defect. Both releases, along with the slides we will be reviewing on today's call, are available on the investor section of Collar's website at www.collarrx.com. We will begin the call with prepared remarks by Mark Iwiki, our Chairman, President, and Chief Executive Officer, Kim Brazel, our Chief Medical Officer, Todd Bazemore, our Chief Operating Officer, and Mary Remus, Chief Financial Officer. Then we will open the call up for questions. During this call, we will be referring to non-GAAP financial measures which are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly Comparable gap measures is availa...